Literature DB >> 20738466

Reasons for non-use of proven pharmacotherapeutic interventions: systematic review and framework development.

Arden R Barry1, Peter S Loewen, Jane de Lemos, Karen G Lee.   

Abstract

RATIONALE, AIMS AND
OBJECTIVES: The quality of patient care and safety is dependent on addressing both errors of commission (e.g. overuse of medications) and errors of omission (e.g. patients receiving too little care). Despite guidelines recommending the use of certain proven pharmacotherapeutic interventions, a large gap exists between the patients that have an indication for, and those that actually receive such interventions. To address how the rate of implementation of proven interventions can be improved is dependent on a comprehensive knowledge of the factors contributing to their underuse. The aim of the review is to create an evidence-based framework of reasons why eligible patients do not receive proven pharmacotherapeutic interventions.
METHODS: A systemic review of the published reasons for non-use based on the Cochrane methodology.
RESULTS: The systematic review identified 67 articles meeting the inclusion criteria. The reasons for non-use were extracted from the studies and a framework was created from the results.
CONCLUSIONS: The factors associated with lack of implementation of proven pharmacotherapeutic interventions are complex and heterogeneous but can be understood from the perspectives of clinicians, patients and health care delivery systems. Efforts to increase the utilization of proven interventions should focus on disease/intervention-specific programmes that take into account the identified modifiable clinician, patient and system factors.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20738466     DOI: 10.1111/j.1365-2753.2010.01524.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  4 in total

1.  Impact of an enhanced pharmacy discharge service on prescribing appropriateness criteria: a randomised controlled trial.

Authors:  Benjamin J Basger; Rebekah J Moles; Timothy F Chen
Journal:  Int J Clin Pharm       Date:  2015-08-22

2.  Implementation of the Canadian Paediatric Society's hyperbilirubinemia guidelines: A survey of Ontario hospitals.

Authors:  Elizabeth Kathleen Darling; Astrid Guttmann; Ann E Sprague; Timothy Ramsay; Mark C Walker
Journal:  Paediatr Child Health       Date:  2014-03       Impact factor: 2.253

3.  Barriers to and Enablers of Implementation of High-Value Interventions by Renal Pharmacists: A Qualitative Study Informed by the Theoretical Domains Framework.

Authors:  William Nevers; Alice Ratcheva; Kate Boutin; Sean K Gorman; Richard Slavik; Natalie Lesko
Journal:  Can J Hosp Pharm       Date:  2020-06-01

4.  The timing of introduction of pharmaceutical innovations in seven European countries.

Authors:  Ragnar Westerling; Marcus Westin; Martin McKee; Rasmus Hoffmann; Iris Plug; Grégoire Rey; Eric Jougla; Katrin Lang; Kersti Pärna; José L Alfonso; Johan P Mackenbach
Journal:  J Eval Clin Pract       Date:  2014-04-22       Impact factor: 2.431

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.